Plerixafor is an immunostimulant
that mobilizes hematopoietic stem cells in cancer patients.
A chitosan derivative, glycated chitosan (GC), has been used as an immunostimulant
for cancer treatment in laser immunotherapy.
The alliance designed Fibosel[R], which has become today an immunostimulant
of reference with worldwide uses in a variety of animal species, especially aquatic species and young and breeding monogastric animals.
Andrographis contains andrographolide, a component that has shown effective immunostimulant
and antiinflammatory properties that may assist in relieving uncomplicated URTI.
Including more than one immunostimulant
within an adjuvant has the capacity to improve the quality of the immune response to a vaccine.
David Claxton at Penn State University (State College, PA) for the development of immunostimulant
and therapeutic vaccine approaches for the treatment of acute myelogenous leukemia (AML).
Carrington is a research-based biopharmaceutical company currently utilizing naturally-occurring polysaccharides to produce Acemannan Immunostimulant
, an injectable biologic for the treatment of fibrosarcoma in cats and dogs; Acemannan Hydrogel used in products for radiation dermatitis, and other wound and oral care applications; and a variety of polysaccharide raw materials for use in dietary supplement formulations.
Carrington currently holds approximately 120 patents, issued and pending, in 26 countries under which it manufactures its drug product Aliminase currently in Phase III clinical trials for the treatment of ulcerative colitis; Acemannan Immunostimulant
, an injectable as an adjunct for the treatment of fibrosarcoma in dogs and cats; raw materials, such as Manapol Powder used in a variety of consumer and nutraceutical products; and acemannan hydrogel used in Carrington's proprietary wound care products.
Pink Sheets: ATKJ), has improved Tubercin T-5 an immunostimulant
Amgen's blockbuster brands Neulasta (pegfilgrastim) and Neupogen (filgrastim) dominated the immunostimulant
market in 2007, with sales of $3.
The data will cover the consistency in multiple species of JuvImmune immunostimulant
and JuvaVax products being developed for HIV, influenza, hepatitis and HSV-2.
6 /PRNewswire-FirstCall/ -- Iomai Corporation today announced that it has begun dosing in a Phase 1/2 study that will assess the safety and dose-sparing capability of the company's immunostimulant
patch when used in combination with an injected H5N1 influenza vaccine.